A Phase 1 interventional study of AZD9550 solution for injection and AZD6234 solution for injection in Healthy Participants, sponsored by AstraZeneca. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
This study will take place at one site in Nottingham, United Kingdom, and will randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of two test medicines, AZD9550 and AZD6234.
This study will take place at one site in Nottingham, United Kingdom.
It plans to randomize 60 healthy men and women aged 18-55 years living with overweight/obesity.
Each volunteer will receive a single dose of test medicine by injection under the skin into the abdomen (tummy), either as 2 separate injections (one of each test medicine) or as a single injection where the test medicines are combined. They'll stay in the clinic for 6 nights on 1 occasion, attend up to 5 outpatient visits, and take up to 9 weeks to finish the study.
Blood and urine samples will be collected to measure the amounts of AZD6234 and AZD9550 and a component of the test medicine, do safety tests, and assess the effect of the test medicine on the immune system.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 60 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →AstraZeneca is the lead sponsor of 3,499 studies on the registry; 270 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single concomitant SC injections of AZD9550 solution for injection and AZD6234 solution for injection
Drug: AZD9550 solution for injection · Drug: AZD6234 solution for injection
Participants will receive a single SC injection of Formulation 1 solution for injection
Drug: Formulation 1 solution for injection
Participants will receive a single SC injection of Formulation 2 solution for injection
Drug: Formulation 2 solution for injection
Participants will receive a single SC injection of Formulation 3 solution for injection
Drug: Formulation 3 solution for injection
Participants will receive a single SC injection of Formulation 4 solution for injection
Drug: Formulation 4 solution for injection
AZD9550 solution for injection will be administered as a single SC injection
Also known as: AZD9550
AZD6234 solution for injection will be administered as a single SC injection
Also known as: AZD6234
Formulation 1 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Formulation 2 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Formulation 3 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Formulation 4 solution for injection will be administered as a single SC injection
Also known as: AZD9550+AZD6234
Maximum observed plasma concentration (Cmax)
Assess the relative bioavailability (rBA) and compare single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Area under the curve from time 0 to the time of last quantifiable concentration (AUClast)
Assess the relative bioavailability (rBA) and compare the single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Area under the curve from time 0 extrapolated to infinity (AUCinf)
Assess the relative bioavailability (rBA) and compare the single subcutaneous (SC) dose pharmacokinetics (PK) of concomitant doses of AZD9550 and AZD6234 to different fixed-dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Number of participants with adverse events (AEs)/serious AEs (SAEs), and change from baseline for vital signs, electrocardiograms (ECGs), and laboratory safety tests
Safety and tolerability of single concomitant doses and different fixed-dose coformulations of AZD9550 and AZD6234 following a single subcutaneous (SC) dose
Time frame: Through study duration, approximately 9 weeks
Time of maximum observed concentration (tmax)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Time of last measurable observed concentration (tlast)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformuations
Time frame: Plasma sample collection from pre dose to Day 22
Time prior to the first measurable concentration (tlag)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Terminal elimination half-life (t1/2λz)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Apparent total body clearance (CL/F)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Apparent volume of distribution based on the terminal phase (Vz/F)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Mean residence time from time 0 extrapolated to infinity (MRTinf)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
First order rate constant associated with the terminal (log-linear) portion of the curve (λz)
Evaluate the pharmacokinetics (PK) of AZD9550 and AZD6234 following a single subcutaneous (SC) concomitant administration or administration as different fixed dose coformulations
Time frame: Plasma sample collection from pre dose to Day 22
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2027, 5 months later.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 5 months is below that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: AZD9550 · AZD6234